Labcorp Holdings Inc.

Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026

Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center, and at-home settings Through a network serving more than 850,000 physicians and healthcare providers and more than 2,200 patient service centers, Labcorp is helping expand access to cervical cancer screening nationwide First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping MILFORD, Mass. and BURLINGTON, N.C.

Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential

Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions BURLINGTON, N.C., Oct. 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused.

LH vs. DHR: Which Stock Is the Better Value Option?

Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

Labcorp Prepares to Report Q3 Earnings: What's in the Cards?

LH's Q3 earnings may benefit from strong diagnostics demand, specialty testing expansion and acquisitions, with revenues projected to grow 5.7%.

Labcorp Declares Quarterly Dividend

BURLINGTON, N.C., Oct. 21, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

Labcorp Holdings Inc. (NYSE:LH) has agreed to acquire the prenatal health testing business of Myriad Genetics Inc. (NASDAQ:MYGN) in an all-cash transaction valued at $210 million, plus the value of the unit's inventory upon closing.

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel®, Foresight®, SneakPeek®, and FirstGene® tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing business at closing.

Labcorp Holdings Inc. $LH Shares Sold by Birch Hill Investment Advisors LLC